MedTrace Logo

TAVI and Gender Outcomes Aortic Stenosis Undergoing Transfemoral Transcatheter Aortic Valve Implantation.

NCT04915976 · Status: SUSPENDED · Type: OBSERVATIONAL · Enrollment: 14086

Last updated 2023-12-21

No results posted yet for this study

Summary

Severe aortic stenosis (AS) is the commonest form of valvular abnormality in the developed world and transcatheter aortic valve implantation (TAVI) is now widely practiced as in many cases is the preferred treatment option over conventional aortic surgery. Several studies have shown that females have an apparent better outcome with TAVI than males.

There are a number of possible reasons as to the apparent favourable benefit of TAVI in women including: having both lower rates of moderate / severe aortic regurgitation and peri-procedural mortality, lower rates of bleeding and renal failure, better patient prosthesis match and recovery of left ventricular function with more favourable left ventricular remodelling.

We aim to explore the long term outcomes of TAVI between males and females to try and identify specific tailored treatment options.

This data will be useful in providing important information regarding gender differences in patients who are treated with transcatheter aortic valve implantation. Data provided will include long term outcomes and predictors of outcome.

The study team will then identify and implement strategies to improve outcomes in patients being treated with transcatheter aortic valve implantation.

Conditions

  • Aortic Stenosis
  • Gender
  • Surgery

Sponsors & Collaborators

  • Imperial College Healthcare NHS Trust

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2017-01-31
Completion
2025-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04915976 on ClinicalTrials.gov